The case for continuous prenatal care: what daily monitoring adds to antenatal pathways

For a low-risk, first-time pregnancy, the standard NHS antenatal schedule includes around ten appointments across forty weeks. A subsequent low-risk pregnancy typically involves seven. Refined over decades of clinical evidence, these schedules reflect where professional oversight offers the greatest value in relation to available clinical resource. By the evidence, they are appropriate for the population they serve.

Yet pregnancies that progress well on that schedule are not necessarily progressing well because of it. For a significant proportion, appointments are not frequent enough to capture individual changes that could benefit from earlier identification. The schedule is not wrong in aggregate. The issue is that individual pregnancy risk does not follow population averages.

This article considers the structural case for continuous daily monitoring alongside standard antenatal care. It distinguishes where that case is strong, where it remains speculative, and what it does and does not mean for practice.

The gap is structural, not clinical effort

The gap in antenatal monitoring does not reflect inadequate clinical care. Midwives and obstetricians in the NHS provide the level of care supported by the evidence and available resource. The gap is structural, built into any system where oversight occurs at separate points in time rather than continuously.

Between appointments, the clinical picture is reconstructed from the parent's memory and the reading taken at the visit. If a symptom began three weeks before the appointment, peaked ten days ago, and has partly resolved, the visit captures neither its peak nor its trajectory. The clinician sees the current reading and hears the parent's account. Without systematic tracking, that account is necessarily approximate.

This is not a criticism of any part of the pathway. It describes what periodic care can structurally capture compared with what daily observation over time can capture. The two approaches complement one another rather than compete.

The conditions most sensitive to early identification

The gap between appointments does not affect every pregnancy complication equally. Some develop acutely and need emergency clinical action regardless of the monitoring interval. Others develop gradually over days or weeks, making their trajectory particularly relevant to earlier identification.

Gestational hypertension and pre-eclampsia sit firmly in the second category. Blood pressure in pregnancy typically rises gradually. A single borderline clinic reading may be monitored and repeated. A week of home readings showing a consistent upward trend gives a clinically different input to the same decision. The trend is more informative than the current value alone.

Changes in foetal movement can also develop over several days. A parent who notices less movement than usual over the past three days has different information from one who notices reduced movement today. The former account gives the clinician more useful information when assessing whether urgent review is warranted.

Intrauterine growth restriction (IUGR) is generally identified through fundal height measurement and ultrasound, not symptom logging. Daily parental monitoring cannot identify it. It does, however, illustrate a broader point: continuous monitoring is most suited to conditions with gradual onset and a window in which clinical intervention can alter the trajectory.

What daily monitoring means here

In consumer digital health, "continuous monitoring" does not mean the medical-grade continuous telemetry used for a high-risk obstetric patient in hospital. It means a daily record of relevant self-reported observations: movement patterns, blood pressure if applicable, symptoms, and general wellbeing. The data is self-reported rather than clinician-verified, and its clinical weight reflects that.

This distinction matters. A home blood pressure reading taken by a parent is not equivalent to one taken in a clinical setting with calibrated equipment by a trained clinician who can consider it alongside other physical findings. They are different types of information.

A daily log provides a trend over time from one consistent observer under consistent conditions. Noise in individual readings can average out across multiple readings. A trend across ten or twenty readings contains more signal than a single observation. For detecting gradual change, it is useful because it records what happens between scheduled appointments.

The clinical workflow question

To create clinical value, continuous monitoring must reach the care team in a usable form. This is where much of the practical work lies, and where many consumer health tools fall short. A log kept only on the parent's phone, unseen by the midwife and difficult for the parent to summarise under pressure, offers limited clinical value however complete it is.

The connection between the parent's record and the clinical pathway matters greatly. A midwife receiving a structured summary of a patient's monitoring over the past two weeks, arranged by relevant parameters, is in a different position from one hearing, "I have been tracking on my phone, and I think things have been fairly normal." The summary turns a personal log into clinical input.

This is a central design constraint in building Materai. A log maintained by a parent but never seen by a clinician has one kind of value, mainly for the parent. A log that creates a structured pre-appointment summary for a clinician to review in two minutes has another. The route from observation to clinical conversation must be short and easy to use. Otherwise, monitoring remains in the consumer layer and does not reach the clinical layer where it could do the most work.

The honest limits of this argument

I believe the structural case for continuous daily monitoring alongside scheduled antenatal care is sound. Its specific clinical impact, measured through outcomes, is a separate question that properly designed prospective studies must answer rigorously. That evidence does not yet exist for consumer digital monitoring tools specifically. We are at an early stage of building towards it, within the constraints of our scale and stage.

We have a sound theoretical basis, early observations from our initial cohort pointing in the expected direction, and a clear view of the next steps towards stronger evidence. We do not claim that using Materai changes outcomes. We are building the infrastructure to establish whether it does, while making a product we believe is useful in the meantime, based on first principles and early signal.

The gap in antenatal care between appointments is real. The field is actively considering how best to address it and what evidence base is needed. Daily monitoring is not the only answer, nor is it right for every pregnancy. It is a credible part of the answer and deserves serious consideration as the tools become more accessible and more able to fit into clinical workflows.

Where we go next

For continuous prenatal monitoring to move from a structural case to a clinical standard, several things must happen. The evidence base must extend beyond high-acuity settings to community-based low-risk and moderate-risk pregnancy populations. Tools must show consistent, reliable integration into clinical workflows rather than operate as parallel consumer products. The clinical community must also establish clear guidance on the level of self-reported monitoring suitable for each risk category.

None of this will happen quickly. What can happen sooner is creating products that are genuinely useful to parents and accessible to clinicians, collecting observational data to support better-designed prospective studies, and staying honest about what is known, expected, and still to be established.

That is the work we are doing. The structural case is clear, while the evidence case is still being built. Both can be true at once. Being clear about both is, we believe, the right basis for building something with lasting value in maternity care.